Trial reportJournal of cellular and molecular medicine2025
Association of Triglyceride-Glucose Index With Different Cardiovascular Diseases in Non-Diabetic Hypertension.
Trial report in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of Triglyceride-Glucose Index With Different Cardiovascular Diseases in Non-Diabetic Hypertension.Journal of cellular and molecular medicine · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This research intends to explore the association of the triglyceride-glucose (TyG) index with cardiovascular disease (CVD) death, stroke, myocardial infarction (MI), heart failure (HF) and peripheral arterial disease (PAD) in non-diabetic hypertension. This post hoc analysis uses data from a large-scale randomised controlled trial (RCT) study-Systolic Blood Pressure Intervention Trial (SPRINT), and we used Cox proportional hazards regression to explore the relationship between TyG and different CVDs. This longitudinal analysis of 9323 participants revealed a significant positive association between the TyG index and CVD death (HR 1.91, 95% CI 1.34, 2.73), HF (HR 1.43, 95% CI 1.05, 1.94), MI (HR 1.30, 95% CI 1.00, 1.69), stroke (HR 1.60, 95% CI 1.16, 2.21) and PAD (HR 1.78, 95% CI 1.30, 2.44). This positive correlation was consistently observed across different subgroups. Trend tests were significant for CVD death, heart failure, MI, stroke and PAD (p < 0.05). In non-diabetic hypertensive patients, a higher TyG index was associated with a higher risk of CVD (CVD death, stroke, HF, MI, PAD).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.